Two Different Regimens of Nolvadex in Preventing Gynecomastia Induced by Casodex 150 mg in Patients With Prostate Cancer

• Status: Completed
• Trial end date: 2007-10-01
• Target enrollment: 0
• Participant gender: Male

Summary

The aim of the study is to investigate the efficacy of different dosing and scheduling of Nolvadex in preventing gynecomastia/mastalgia induced by Casodex 150 mg monotherapy in patients with prostate cancer.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Bicalutamide; Tamoxifen

Criteria

Inclusion Criteria:

• Histologically confirmed prostate cancer

• Locally advanced prostate cancer patients suitable for Casodex 150 mg monotherapy

Exclusion Criteria:

• Age > 75 yrs

• No metastatic disease (M1).

• No presence of gynaecomastia and/or mastalgia at screening

• No therapy with medications able to provoke gynaecomastia and/or mastalgia within 6 months of trial entry.